Navidea Biopharma (NAVB) Reports Q2 Loss of $0.24

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Navidea Biopharma (NAVB) Reports Q2 Loss of $0.24

Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial Results

August 8, 2019 4:05 PM EDT

Conference Call to be held Thursday, August 8, 2019 at 5:00 pm EDT

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter of 2019. Navidea reported total revenues for the quarter of $260,000. Net loss attributable to common stockholders was $2.7 million.

During the second quarter, Navidea continued to deliver on its renewed focus to complete its NAV 3-31 trial and raise the funding to cover it, said Mr. Jed... More